CN105535448B - Traditional Chinese medicine composition for treating children myasthenia gravis - Google Patents
Traditional Chinese medicine composition for treating children myasthenia gravis Download PDFInfo
- Publication number
- CN105535448B CN105535448B CN201610129957.5A CN201610129957A CN105535448B CN 105535448 B CN105535448 B CN 105535448B CN 201610129957 A CN201610129957 A CN 201610129957A CN 105535448 B CN105535448 B CN 105535448B
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- traditional chinese
- myasthenia gravis
- medicine composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 57
- 239000000203 mixture Substances 0.000 title claims abstract description 41
- 206010028417 myasthenia gravis Diseases 0.000 title claims abstract description 20
- 238000000034 method Methods 0.000 claims abstract description 15
- 241000132012 Atractylodes Species 0.000 claims abstract description 12
- 235000002722 Dioscorea batatas Nutrition 0.000 claims abstract description 12
- 240000001811 Dioscorea oppositifolia Species 0.000 claims abstract description 12
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 claims abstract description 12
- 244000303040 Glycyrrhiza glabra Species 0.000 claims abstract description 12
- 235000006533 astragalus Nutrition 0.000 claims abstract description 12
- 241000007126 Codonopsis pilosula Species 0.000 claims abstract description 11
- 235000006536 Dioscorea esculenta Nutrition 0.000 claims abstract description 11
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 11
- 210000000582 semen Anatomy 0.000 claims abstract description 11
- 241000096284 Gynochthodes officinalis Species 0.000 claims abstract description 10
- 235000017784 Mespilus germanica Nutrition 0.000 claims abstract description 10
- 244000182216 Mimusops elengi Species 0.000 claims abstract description 10
- 235000000560 Mimusops elengi Nutrition 0.000 claims abstract description 10
- 235000007837 Vangueria infausta Nutrition 0.000 claims abstract description 10
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims abstract description 10
- 235000011477 liquorice Nutrition 0.000 claims abstract description 10
- 241000759833 Cornus officinalis Species 0.000 claims abstract description 9
- 239000002994 raw material Substances 0.000 claims abstract description 9
- 241000382455 Angelica sinensis Species 0.000 claims abstract description 6
- 241000045403 Astragalus propinquus Species 0.000 claims abstract description 6
- 238000002360 preparation method Methods 0.000 claims description 28
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 18
- 238000002156 mixing Methods 0.000 claims description 13
- 239000000463 material Substances 0.000 claims description 12
- 238000001914 filtration Methods 0.000 claims description 11
- 239000006187 pill Substances 0.000 claims description 9
- 239000000843 powder Substances 0.000 claims description 9
- 238000010298 pulverizing process Methods 0.000 claims description 9
- 239000002775 capsule Substances 0.000 claims description 8
- 239000002552 dosage form Substances 0.000 claims description 8
- 239000000706 filtrate Substances 0.000 claims description 8
- 239000008187 granular material Substances 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 7
- 241001061264 Astragalus Species 0.000 claims description 6
- 235000001287 Guettarda speciosa Nutrition 0.000 claims description 6
- 240000001341 Reynoutria japonica Species 0.000 claims description 6
- 235000018167 Reynoutria japonica Nutrition 0.000 claims description 6
- 238000004140 cleaning Methods 0.000 claims description 6
- 238000000643 oven drying Methods 0.000 claims description 6
- 239000003826 tablet Substances 0.000 claims description 6
- 210000004233 talus Anatomy 0.000 claims description 6
- 244000061520 Angelica archangelica Species 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 4
- 239000006188 syrup Substances 0.000 claims description 4
- 235000020357 syrup Nutrition 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 3
- 238000000227 grinding Methods 0.000 claims description 3
- 239000006186 oral dosage form Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000001376 precipitating effect Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 13
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 11
- 238000003756 stirring Methods 0.000 description 10
- 229940079593 drug Drugs 0.000 description 8
- 239000002671 adjuvant Substances 0.000 description 7
- 229920002472 Starch Polymers 0.000 description 6
- 239000008107 starch Substances 0.000 description 6
- 235000019698 starch Nutrition 0.000 description 6
- 238000005303 weighing Methods 0.000 description 6
- 239000012530 fluid Substances 0.000 description 5
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 4
- CNLSPQQMAJCIFB-UHFFFAOYSA-N benzoic acid;ethanol Chemical compound CCO.OC(=O)C1=CC=CC=C1 CNLSPQQMAJCIFB-UHFFFAOYSA-N 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 235000010241 potassium sorbate Nutrition 0.000 description 4
- 239000004302 potassium sorbate Substances 0.000 description 4
- 229940069338 potassium sorbate Drugs 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 229920001353 Dextrin Polymers 0.000 description 3
- 239000004375 Dextrin Substances 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 239000000544 cholinesterase inhibitor Substances 0.000 description 3
- 235000019425 dextrin Nutrition 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 235000010199 sorbic acid Nutrition 0.000 description 3
- 239000004334 sorbic acid Substances 0.000 description 3
- 229940075582 sorbic acid Drugs 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 241000209020 Cornus Species 0.000 description 2
- 239000002202 Polyethylene glycol Chemical class 0.000 description 2
- 208000032023 Signs and Symptoms Diseases 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 239000001913 cellulose Chemical class 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Chemical class 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 125000004494 ethyl ester group Chemical group 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 229960002362 neostigmine Drugs 0.000 description 2
- LULNWZDBKTWDGK-UHFFFAOYSA-M neostigmine bromide Chemical compound [Br-].CN(C)C(=O)OC1=CC=CC([N+](C)(C)C)=C1 LULNWZDBKTWDGK-UHFFFAOYSA-M 0.000 description 2
- -1 patches Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229920001223 polyethylene glycol Chemical class 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 229940126680 traditional chinese medicines Drugs 0.000 description 2
- 241000906579 Actaea cimicifuga Species 0.000 description 1
- 229910002012 Aerosil® Inorganic materials 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 241000533865 Callerya reticulata Species 0.000 description 1
- 108010009685 Cholinergic Receptors Proteins 0.000 description 1
- 241000756943 Codonopsis Species 0.000 description 1
- 208000028399 Critical Illness Diseases 0.000 description 1
- 241000110637 Cuscuta chinensis Species 0.000 description 1
- 206010013887 Dysarthria Diseases 0.000 description 1
- 108010010803 Gelatin Chemical class 0.000 description 1
- 240000002045 Guettarda speciosa Species 0.000 description 1
- 235000017443 Hedysarum boreale Nutrition 0.000 description 1
- 235000007858 Hedysarum occidentale Nutrition 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 244000241838 Lycium barbarum Species 0.000 description 1
- 235000015459 Lycium barbarum Nutrition 0.000 description 1
- 235000015468 Lycium chinense Nutrition 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000157491 Morinda Species 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 244000197580 Poria cocos Species 0.000 description 1
- 235000008599 Poria cocos Nutrition 0.000 description 1
- RVOLLAQWKVFTGE-UHFFFAOYSA-N Pyridostigmine Chemical compound CN(C)C(=O)OC1=CC=C[N+](C)=C1 RVOLLAQWKVFTGE-UHFFFAOYSA-N 0.000 description 1
- 244000184734 Pyrus japonica Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 208000037432 Thymic tumor Diseases 0.000 description 1
- 208000000728 Thymus Neoplasms Diseases 0.000 description 1
- 102000034337 acetylcholine receptors Human genes 0.000 description 1
- 230000036982 action potential Effects 0.000 description 1
- 230000001004 anti-acetylcholinic effect Effects 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000002567 electromyography Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 208000017561 flaccidity Diseases 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Chemical class 0.000 description 1
- 229920000159 gelatin Chemical class 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000007383 nerve stimulation Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000017524 noni Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 229960002290 pyridostigmine Drugs 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000026473 slurred speech Diseases 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 201000009377 thymus cancer Diseases 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/233—Bupleurum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/344—Codonopsis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/39—Convolvulaceae (Morning-glory family), e.g. bindweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/40—Cornaceae (Dogwood family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/486—Millettia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/746—Morinda
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/894—Dioscoreaceae (Yam family)
- A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8968—Ophiopogon (Lilyturf)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a traditional Chinese medicine composition for treating children myasthenia gravis, which is prepared from the following traditional Chinese medicine raw materials in parts by weight: 10-120 parts of astragalus membranaceus, 10-30 parts of codonopsis pilosula, 10-20 parts of bighead atractylodes rhizome, 5-8 parts of radix bupleuri, 5-8 parts of rhizoma cimicifugae, 5-10 parts of angelica sinensis, 5-10 parts of cornus officinalis, 5-10 parts of morinda officinalis, 5-10 parts of semen cuscutae, 8-24 parts of Chinese yam, 6-30 parts of radix polygoni multiflori preparata, 5-12 parts of caulis spatholobi, 5-12 parts of medlar, 3-6 parts of liquorice, 3-6 parts of pericarpium citri reticulatae and 3-10 parts of radix ophiopogonis. The traditional Chinese medicine provided by the invention is reasonable in compatibility, free of toxic and side effects, convenient to process, low in cost, obvious in effect of treating the myasthenia gravis of children, and suitable for clinical popularization and application.
Description
Technical Field
The invention belongs to the field of medicines, and relates to a traditional Chinese medicine composition for treating myasthenia gravis of children.
Background
Myasthenia gravis is one of the intractable diseases of the nervous system, and the symptoms are as follows: drooping of the eyelids on one or both sides, weakness of the limbs, difficulty swallowing and slurred speech.
Traditionally, people use three methods of anticholinesterase drugs, thymectomy and radiotherapy to treat myasthenia gravis, but anticholinesterase drugs such as neostigmine and pyridostigmine are temporary and locally effective drugs, which only can temporarily delay the attack of diseases, and long-term administration can cause damage to acetylcholine receptors in human bodies, so that the diseases are more serious. There are also many reports of serious side effects in medical applications using anticholinesterase drugs. On one hand, the curative effect is not ideal by surgical methods such as thymus resection and radiotherapy, and the effect of more than five years is to be observed; on the other hand, the operation method can only be used for patients with myasthenia gravis with the symptoms of thymic tumor, and the application range is narrow. The newly appeared plasma exchange principle in recent years can only be used for critically ill myasthenia gravis patients, the curative effect can only be maintained for about two weeks, the cost is high, and the practical value is low.
According to the traditional Chinese medicine, the myasthenia gravis belongs to flaccidity symptoms in the traditional Chinese medicine category, so that the traditional Chinese medicine is adopted for treating the myasthenia gravis in a targeted manner to achieve a certain effect.
Disclosure of Invention
The traditional Chinese medicine composition is simple in preparation method, good in curative effect, safe to use, free of side effects and suitable for being widely applied clinically.
In order to achieve the purpose, the invention adopts the following technical scheme:
the invention provides a traditional Chinese medicine composition for treating myasthenia gravis of children, which is prepared from the following traditional Chinese medicine raw materials in parts by weight: 10-120 parts of Astragalus (Astragalus membranaceus (Fisch.) Bge.), 10-30 parts of CODONOPSIS pilosula (RADIX Codonopsis), 10-20 parts of bighead Atractylodes rhizome (Atractylodes macrocepha), 5-8 parts of RADIX Bupleuri (RADIX Bupleuri), 5-8 parts of RHIZOMA CIMICIFUGAE (RHIZOMA Cimicifugae), 5-10 parts of Angelica (Angelica sinensis (Oliv.) Diels.), 5-10 parts of dogwood (Cornus officinalis Sieb. Et Zucc) and 5-10 parts of Morinda officinalis (Morinda), 5-10 parts of semen cuscutae (Cuscuta chinensis Lam.), 8-24 parts of Chinese yam (Dioscorea opposita), 6-30 parts of radix polygoni multiflori preparata (cntRoa), 5-12 parts of caulis spatholobi (Millettia reticulata Benth.), 5-12 parts of medlar (Fructus Lycii), 3-6 parts of liquorice (Glycyrriza Uralensis Fisch.G. Glabra L.), 3-6 parts of dried orange peel (PERICARPIUM) and 3-10 parts of radix ophiopogonis (Ophiogon japonica (Linn.f.) Ker-Gawl.).
Further, the traditional Chinese medicine composition is prepared from the following traditional Chinese medicine raw materials in parts by weight: 60 parts of astragalus, 20 parts of codonopsis pilosula, 15 parts of bighead atractylodes rhizome, 6 parts of radix bupleuri, 6 parts of cimicifugae foetidae, 7 parts of angelica, 7 parts of cornus officinalis, 7 parts of morinda officinalis, 7 parts of semen cuscutae, 16 parts of Chinese yam, 18 parts of prepared fleece-flower root, 8 parts of caulis spatholobi, 8 parts of medlar, 5 parts of liquorice, 4 parts of dried orange peel and 6 parts of radix ophiopogonis.
The invention provides a medicinal preparation for treating myasthenia gravis of children, which comprises the traditional Chinese medicine composition.
Furthermore, the dosage form of the pharmaceutical preparation is a conventional dosage form in pharmaceutics. The dosage forms include, but are not limited to, tablets, capsules, pills, granules, suspensions, powders, dripping pills, oral liquids, injections, infusions, freeze-dried powder injections, ointments, gels, patches, suppositories and the like. Preferred dosage forms are oral dosage forms such as tablets, capsules, pills, granules, syrups, mixtures and the like.
Further, the pharmaceutical preparation further comprises a pharmaceutically acceptable carrier, and the pharmaceutically acceptable carrier of the present invention includes but is not limited to:
diluent agent: starch, powdered sugar, lactose, dextrin, microcrystalline cellulose, inorganic salts, sugar alcohols, etc.
Wetting agent and binder: purified water, ethanol, gelatin, polyethylene glycol, cellulose derivatives, and the like.
Disintegrating agent: starch, sodium carboxymethyl starch, cellulose derivatives, crospovidone, and the like.
Lubricant: magnesium stearate, aerosil, talcum powder, polyethylene glycol and the like.
Cosolvent: water, ethanol, glycerol, propylene glycol, liquid paraffin, vegetable oil, etc.
Flavoring agent: sucrose, monosaccharide, aromatic, etc.
Preservative: benzoic acid, sorbic acid, methyl esters, ethyl esters, propyl esters, and the like.
Other suitable auxiliary materials can be added in the preparation process according to requirements, and the application of the auxiliary materials is well known in the field of preparation. The skilled person can select from the available formulation adjuvants according to the needs of the actual formulation.
The traditional Chinese medicine composition can be prepared by the following method: cleaning the medicinal materials, oven drying, grinding into fine powder, mixing, adding appropriate medicinal adjuvants, and making into pharmaceutically acceptable dosage forms such as tablet, capsule, pill, granule, etc.
The invention also provides a preparation method of the traditional Chinese medicine composition, which comprises the following steps: cleaning the Chinese medicinal materials, oven drying, pulverizing, extracting with common extraction solvent such as water and ethanol for several times, mixing extractive solutions, filtering, and concentrating the filtrate to obtain extract. Then drying the paste, pulverizing, adding appropriate pharmaceutical adjuvants, and making into pharmaceutically acceptable dosage forms such as tablet, capsule, pill, granule, etc.
As an alternative technical solution, the preparation method comprises the following steps: cleaning part of the Chinese medicinal materials, oven drying, pulverizing, extracting with common extraction solvent such as water and ethanol for several times, mixing extractive solutions, filtering, and concentrating the filtrate to obtain extract. Then drying and pulverizing the paste. The rest part of the Chinese medicinal materials are ground, pulverized, mixed with paste powder, and added with proper pharmaceutical adjuvants to make into pharmaceutically acceptable dosage forms such as tablet, capsule, pill, granule, etc.
The traditional Chinese medicine composition can also be prepared by the most conventional method of water boiling or alcohol precipitation after water boiling in the field of traditional Chinese medicines.
The traditional Chinese medicine composition can also be prepared by the following steps: cleaning the Chinese medicinal materials, oven drying, grinding into fine powder, and mixing.
The invention provides an application of the traditional Chinese medicine composition in preparing a medicine for treating children myasthenia gravis.
The invention provides application of the medicinal preparation in preparing a medicament for treating the myasthenia gravis of children.
The invention has the following advantages and beneficial effects:
the traditional Chinese medicine composition has the advantages of rich and natural sources, simple preparation process, low preparation cost, good curative effect, safety and no side effect, and is suitable for clinical popularization and use.
Detailed Description
For a better understanding and practice, the present invention is further illustrated below with reference to the following examples. Unless otherwise specified, the examples of the present invention are only for explaining the present invention and are not meant to limit the scope of the present invention.
The traditional Chinese medicine composition and the pharmaceutical preparation are prepared by scientific formula screening on the premise of applying the theoretical basis of traditional Chinese medicine and refining and processing on the premise of applying the scientific extraction process of traditional Chinese medicines.
EXAMPLE 1 preparation of the Chinese medicinal composition
1. Accurately weighing the following traditional Chinese medicine raw materials: 10 parts of astragalus, 10 parts of codonopsis pilosula, 10 parts of bighead atractylodes rhizome, 5 parts of radix bupleuri, 5 parts of cimicifugae foetidae, 5 parts of angelica, 5 parts of cornus officinalis, 5 parts of morinda officinalis, 5 parts of semen cuscutae, 8 parts of Chinese yam, 6 parts of prepared fleece-flower root, 5 parts of caulis spatholobi, 5 parts of medlar, 3 parts of liquorice, 3 parts of dried orange peel and 3 parts of radix ophiopogonis.
2. Pulverizing the above Chinese medicinal materials, and mixing.
EXAMPLE 2 preparation of the Chinese medicinal composition
1. Accurately weighing the following traditional Chinese medicine raw materials: 120 parts of astragalus, 30 parts of codonopsis pilosula, 20 parts of bighead atractylodes rhizome, 8 parts of radix bupleuri, 8 parts of cimicifugae foetidae, 10 parts of angelica, 10 parts of cornus officinalis, 10 parts of morinda officinalis, 10 parts of semen cuscutae, 24 parts of Chinese yam, 30 parts of prepared fleece-flower root, 12 parts of caulis spatholobi, 12 parts of medlar, 6 parts of liquorice, 6 parts of dried orange peel and 10 parts of radix ophiopogonis.
2. The above traditional Chinese medicine raw materials are decocted with five times of water twice, two hours each time. Filtering, mixing filtrates, standing for 48 hr, collecting supernatant, concentrating under reduced pressure to obtain fluid extract, pulverizing into fine powder, or concentrating under reduced pressure to obtain soft extract.
EXAMPLE 3 preparation of the Chinese medicinal composition
1. Accurately weighing the following traditional Chinese medicine raw materials: 60 parts of astragalus, 20 parts of codonopsis pilosula, 15 parts of bighead atractylodes rhizome, 6 parts of radix bupleuri, 6 parts of cimicifugae foetidae, 7 parts of angelica, 7 parts of cornus officinalis, 7 parts of morinda officinalis, 7 parts of semen cuscutae, 16 parts of Chinese yam, 18 parts of prepared fleece-flower root, 8 parts of caulis spatholobi, 8 parts of medlar, 5 parts of liquorice, 4 parts of dried orange peel and 6 parts of radix ophiopogonis.
2. Refluxing the above materials with three times of 85% ethanol for three times, one hour each time. Mixing filtrates, concentrating under reduced pressure to obtain fluid extract, pulverizing into fine powder, or concentrating under reduced pressure to obtain soft extract.
EXAMPLE 4 preparation of pharmaceutical formulations
1. Preparation of oral liquid
(1) Preparing the traditional Chinese medicine composition clear paste according to the method in the embodiment 1-the embodiment 3;
(2) adding 20% benzoic acid ethanol solution 5ml and 24% potassium sorbate solution 5ml, stirring, refrigerating for more than 48 hr, filtering, adding water to adjust to content of crude drug 5.5g per ml, stirring, and bottling to obtain oral liquid.
2. Preparation of syrup
(1) Preparing the traditional Chinese medicine composition clear paste according to the method in the embodiment 1-the embodiment 3;
(2) adding adjuvants such as sucrose, sorbic acid, and water, stirring, and making syrup.
3. Preparation of tablets
(1) Preparing the traditional Chinese medicine composition clear paste according to the method in the embodiment 1-the embodiment 3;
(2) adding adjuvants such as starch, ethanol, and pulvis Talci, and making into tablet.
4. Preparation of capsules
(1) Preparing the traditional Chinese medicine composition clear paste according to the method in the embodiment 1-the embodiment 3;
(2) adding adjuvants such as starch, ethanol, dextrin, and magnesium stearate, and making into capsule.
5. Preparation of granules
(1) Preparing the traditional Chinese medicine composition clear paste according to the method in the embodiment 1-the embodiment 3;
(2) adding adjuvants including sugar powder, starch, dextrin, and ethanol, and making into granule.
6. The preparation method of the pill comprises the following steps:
(1) preparing a thick paste of the Chinese medicinal composition according to the method in example 2-example 3;
(2) and (4) making the paste into pills.
7. The preparation method of the mixture comprises the following steps:
(1) preparing a thick extract of the Chinese herbal medicine extract according to the method of example 1-example 3;
(2) adding adjuvants such as sucrose, ethyl ester, water, and sorbic acid, and stirring to obtain mixture.
EXAMPLE 5 therapeutic Effect of the Chinese medicinal composition
1. Preparation of Experimental drugs
Preparation of comparative drug a: weighing 60 parts of astragalus membranaceus, 20 parts of codonopsis pilosula, 15 parts of bighead atractylodes rhizome, 10-30 parts of poria cocos, 10 parts of cimicifuga foetida, 10 parts of radix bupleuri, 10 parts of wolfberry fruit, 10 parts of angelica sinensis, 10 parts of pericarpium citri reticulatae, 5 parts of honey-fried licorice root, 10 parts of semen cuscutae, 10 parts of semen coicis, 10 parts of malt, 10 parts of Chinese yam and 10 parts of cornus pulp. Decocting with five times of water twice, each for two hours, filtering, mixing filtrates, standing for 48 hr, collecting supernatant, and concentrating under reduced pressure to obtain fluid extract; adding 20% benzoic acid ethanol solution 5ml and 24% potassium sorbate solution 5ml, stirring, refrigerating for more than 48 hr, filtering, adding water to adjust to content of crude drug 5.5g per ml, stirring, and bottling to obtain oral liquid.
Preparation of comparative drug B: weighing 120 parts of astragalus membranaceus, 20 parts of radix pseudostellariae, 60 parts of codonopsis pilosula, 20 parts of bighead atractylodes rhizome, 6 parts of radix bupleuri, 6 parts of cimicifugae foetidae, 7 parts of angelica sinensis, 20 parts of Chinese yam, 6 parts of cortex albiziae, 18 parts of prepared fleece-flower root, 7 parts of morinda officinalis, 6 parts of mulberry, 5 parts of liquorice, 4 parts of pericarpium citri reticulatae, 3 parts of fructus aurantii, 20 parts of caulis spatholobi, 10 parts of medlar and 6 parts of radix. Decocting with five times of water twice, each for two hours, filtering, and mixing filtrates. Standing for 48 hr, collecting supernatant, and concentrating under reduced pressure to obtain fluid extract; adding 20% benzoic acid ethanol solution 5ml and 24% potassium sorbate solution 5ml, stirring, refrigerating for more than 48 hr, filtering, adding water to adjust to content of crude drug 5.5g per ml, stirring, and bottling to obtain oral liquid.
The preparation of the traditional Chinese medicine composition of the invention comprises the following steps: weighing 60 parts of astragalus mongholicus, 20 parts of codonopsis pilosula, 15 parts of bighead atractylodes rhizome, 6 parts of radix bupleuri, 6 parts of cimicifugae foetidae, 7 parts of angelica sinensis, 7 parts of cornus officinalis, 7 parts of morinda officinalis, 7 parts of semen cuscutae, 16 parts of Chinese yam, 18 parts of radix polygoni multiflori preparata, 8 parts of caulis spatholobi, 8 parts of medlar, 5 parts of liquorice, 4 parts of pericarpium citri reticulatae and 6 parts of radix ophiopogonis. Decocting with five times of water twice, each for two hours, filtering, mixing filtrates, standing for 48 hr, collecting supernatant, and concentrating under reduced pressure to obtain fluid extract; adding 20% benzoic acid ethanol solution 5ml and 24% potassium sorbate solution 5ml, stirring, refrigerating for more than 48 hr, filtering, adding water to adjust to content of crude drug 5.5g per ml, stirring, and bottling to obtain oral liquid.
2. The test population: the number of children patients is 120, the children patients are randomly divided into 3 groups, and all the patients are confirmed to be myasthenia gravis patients through the following diagnosis standards:
(1) neostigmine test was positive: electromyography checks that the action potential of repeated electrical nerve stimulation is attenuated.
(2) Positive for serum anti-acetylcholine antibody.
Respectively administering a contrast medicament A, a contrast medicament B and the traditional Chinese medicine composition,
the dosage is 150-200ml each time, and the preparation is administered three times daily. The treatment effect was observed after continuous administration for one month.
3. The evaluation standard of curative effect is as follows:
and (3) curing: clinical symptoms and physical signs disappear completely, and no relapse occurs in three months;
the method has the following advantages: improvement in clinical symptoms and signs;
and (4) invalidation: there was no improvement in clinical symptoms and signs.
4. Therapeutic results
The effective rate of the traditional Chinese medicine composition reaches 100%, the effect is better than that of the comparative medicine A and the comparative medicine B, and the specific data are shown in Table 1.
TABLE 1 statistics of efficacy results
The foregoing is a more detailed description of the invention in connection with specific preferred embodiments and it is not intended that the invention be limited to these specific details. For those skilled in the art to which the invention pertains, several simple deductions or substitutions can be made without departing from the spirit of the invention, and all shall be considered as belonging to the protection scope of the invention.
Claims (10)
1. The traditional Chinese medicine composition for treating children myasthenia gravis is characterized by being prepared from the following traditional Chinese medicine raw materials in parts by weight: 10-120 parts of astragalus membranaceus, 10-30 parts of codonopsis pilosula, 10-20 parts of bighead atractylodes rhizome, 5-8 parts of radix bupleuri, 5-8 parts of rhizoma cimicifugae, 5-10 parts of angelica sinensis, 5-10 parts of cornus officinalis, 5-10 parts of morinda officinalis, 5-10 parts of semen cuscutae, 8-24 parts of Chinese yam, 6-30 parts of radix polygoni multiflori preparata, 5-12 parts of caulis spatholobi, 5-12 parts of medlar, 3-6 parts of liquorice, 3-6 parts of pericarpium citri reticulatae and 3-10 parts of radix ophiopogonis.
2. The traditional Chinese medicine composition according to claim 1, which is prepared from the following traditional Chinese medicine raw materials in parts by weight: 60 parts of astragalus, 20 parts of codonopsis pilosula, 15 parts of bighead atractylodes rhizome, 6 parts of radix bupleuri, 6 parts of cimicifugae foetidae, 7 parts of angelica, 7 parts of cornus officinalis, 7 parts of morinda officinalis, 7 parts of semen cuscutae, 16 parts of Chinese yam, 18 parts of prepared fleece-flower root, 8 parts of caulis spatholobi, 8 parts of medlar, 5 parts of liquorice, 4 parts of dried orange peel and 6 parts of radix ophiopogonis.
3. A pharmaceutical preparation for treating myasthenia gravis in children, comprising the Chinese medicinal composition of claim 1 or 2.
4. The pharmaceutical formulation of claim 3, wherein the dosage form of the pharmaceutical formulation is a pharmaceutically conventional oral dosage form.
5. The pharmaceutical formulation according to claim 4, wherein the oral dosage form is oral liquid, syrup, granule, pill, tablet, capsule, mixture.
6. The preparation method of the traditional Chinese medicine composition of claim 1 or 2, which is characterized by comprising the following steps: cleaning the Chinese medicinal materials, oven drying, grinding into fine powder, and mixing.
7. The preparation method of the traditional Chinese medicine composition of claim 1 or 2, which is characterized by comprising the following steps: cleaning the Chinese medicinal materials, oven drying, pulverizing, extracting for several times, mixing extractive solutions, filtering, concentrating the filtrate to obtain extract, drying, pulverizing, and mixing.
8. A method for preparing a Chinese medicinal composition as claimed in claim 1 or 2, wherein the method comprises decocting the Chinese medicinal materials in water or decocting in water and precipitating with ethanol.
9. The use of a Chinese medicinal composition according to claim 1 or 2 in the preparation of a medicament for the treatment of myasthenia gravis in children.
10. Use of a pharmaceutical formulation according to any one of claims 3 to 5 in the manufacture of a medicament for the treatment of myasthenia gravis in children.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610129957.5A CN105535448B (en) | 2016-03-07 | 2016-03-07 | Traditional Chinese medicine composition for treating children myasthenia gravis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610129957.5A CN105535448B (en) | 2016-03-07 | 2016-03-07 | Traditional Chinese medicine composition for treating children myasthenia gravis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105535448A CN105535448A (en) | 2016-05-04 |
| CN105535448B true CN105535448B (en) | 2020-09-29 |
Family
ID=55815356
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610129957.5A Active CN105535448B (en) | 2016-03-07 | 2016-03-07 | Traditional Chinese medicine composition for treating children myasthenia gravis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105535448B (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107115483B (en) * | 2017-05-02 | 2020-09-29 | 马宇振 | Pharmaceutical composition for treating muscular dystrophy and myasthenia and application thereof |
| CN108524775B (en) * | 2018-07-13 | 2021-03-23 | 乞国艳 | Application of traditional Chinese medicine in preparation of medicinal preparation for treating myasthenia gravis combined with thymoma |
| CN108653526B (en) * | 2018-07-13 | 2021-03-16 | 乞国艳 | Traditional Chinese medicine formula for treating myasthenia gravis |
| CN108524748B (en) * | 2018-07-13 | 2021-05-14 | 乞国艳 | Traditional Chinese medicine composition for treating myasthenia gravis combined with rash |
| CN111249437A (en) * | 2020-04-20 | 2020-06-09 | 宋俊青 | Traditional Chinese medicine formula for treating myasthenia gravis |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104069339A (en) * | 2014-06-18 | 2014-10-01 | 乞国艳 | Traditional Chinese medicine composition for treating myasthenia gravis and preparation method thereof |
-
2016
- 2016-03-07 CN CN201610129957.5A patent/CN105535448B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104069339A (en) * | 2014-06-18 | 2014-10-01 | 乞国艳 | Traditional Chinese medicine composition for treating myasthenia gravis and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105535448A (en) | 2016-05-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2016312007B2 (en) | Shenlingbaizhu granules and preparation method thereof | |
| CN105535448B (en) | Traditional Chinese medicine composition for treating children myasthenia gravis | |
| CN102416139B (en) | Chinese medicine composition for treating breast diseases | |
| CN101837065B (en) | Medicine with anti-hepatitis, anti-tumour and organism immunity improving functions and preparation method thereof | |
| AU2015345884B2 (en) | Drug or health care product preventing or treating liver and kidney damage-related diseases and use thereof | |
| CN103230548B (en) | Traditional Chinese medicine composition for treating pulmonary heart disease | |
| CN102119970B (en) | Chinese medicinal composition for treating myasthenia gravis | |
| CN101041010A (en) | A pharmaceutical composition for treating diabetes and its preparation method | |
| CN102552527B (en) | Traditional Chinese medicine composition used for treating diabetic complications and reducing blood sugar and preparation method thereof | |
| CN110507708B (en) | Safflower Xiaoyao preparation for treating hyperplasia of mammary glands and preparation method and application thereof | |
| CN100371012C (en) | Medicinal composition, and its preparing method and use | |
| CN112206285A (en) | Medicine for treating cardiovascular and cerebrovascular diseases | |
| CN107961272B (en) | Traditional Chinese medicine composition for treating chronic kidney diseases | |
| CN101199669A (en) | Chinese medicine compound agent for treating female sperm quality lowclass | |
| CN110917311A (en) | A Chinese medicinal oral liquid for preventing miscarriage and regulating menstrual period and climacteric period, and its preparation method | |
| CN1413697A (en) | Method for preparing Chinese medicine Liuwei Dihuang preparation | |
| CN114366795B (en) | Traditional Chinese medicine composition and medicine for irritable bowel syndrome and preparation method and application thereof | |
| CN109876127B (en) | Blood-nourishing angelica sinensis capsule and preparation method thereof | |
| CN115040577A (en) | Traditional Chinese medicine composition for treating atrophic gastritis with intestinal metaplasia and atypical hyperplasia and preparation method thereof | |
| CN102058771A (en) | Chinese medicine preparation for treating insomnia and preparation method thereof | |
| CN1589839A (en) | Stasis transforming pain relieving particle agent and its preparation method | |
| CN113101330B (en) | Menstruation regulating composition and application thereof | |
| CN1730081A (en) | Medicine for treating cataract eye diseases and preparation method thereof | |
| CN117180365B (en) | Pharmaceutical composition for preventing and/or treating breast cancer, preparation method and application thereof | |
| CN118831133B (en) | Traditional Chinese medicine composition for treating senile dementia and vascular dementia and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |